Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- Is Legal Regulation Necessary? Clinical Research at Turning Point 3: Dr Yamamoto of SCJ
August 8, 2014
- Govt to Enhance Support to Boost Pharma Sector’s Competitiveness: Health Policy Bureau Head
August 7, 2014
- Health Insurance Bureau Chief Says Discussions on Accurate Market Prices and Frequency of NHI Price Revisions Important
August 7, 2014
- MHLW Issues Notification Calling for Compliance with GVP Ministerial Ordinance
August 7, 2014
- MHLW to Survey Rate of Generic Drug Use Under High-Cost Healthcare System; Regulatory Reform Council Concerned that System Provides Little Incentive to Use Generics
August 6, 2014
- PFSB’s Budget Request for FY2015 Will Seek Funding to Strengthen Operations at PMDA: Director-General
August 6, 2014
- MHLW to Remind Drug Makers of Proper ADR Reporting in Wake of Administrative Improvement Order to Novartis
August 4, 2014
- MHLW to Fund Research Aimed at Obtaining Additional Indications for Intractable and Orphan Diseases for Existing Drugs
August 4, 2014
- PAFSC First Committee Backs Approval of MSD’s Insomnia Treatment
August 4, 2014
- JPMA to Examine Clinical Trial Costs
August 1, 2014
- Improvement Order Issued to Novartis over Delayed ADR Reporting
August 1, 2014
- Government to Increase Review Fee for New Generic Drugs from 630,000 Yen to 940,000 Yen
August 1, 2014
- JPA’s Abe Makes Chuikyo Debut, Says No to Annual Drug Price Revisions
July 31, 2014
- Regulatory Review Trend in Japan Signals Pharmas’ Shift to Cancer Drugs: Jiho Tally
July 30, 2014
- MHLW Bulletin Notifies of Revised Package Inserts Warning Concurrent Use of ARBs, ACE Inhibitors
July 30, 2014
- NIBIO Initiates Support for Applied Research on 15 Promising Drug Seeds with Goal of First Licensing Agreement by FY2015
July 30, 2014
- MHLW to Review Criteria for Clinical Research Core Hospitals by April
July 29, 2014
- Revised PAL Mandating Submission of Package Inserts to Minister Will Take Effect on Nov 25
July 29, 2014
- Govt Thought TPP Talks Would Be Wrapped Up Sooner: Official
July 29, 2014
- PAFSC’s Second Committee to Discuss Kyowa Kirin’s Long-Acting G-CSF Drug Pegfilgrastim on August 8
July 29, 2014
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…